🇫🇷 FR
🇫🇷 FR
Case study

International Phase III clinical trial comparing a new molecule combined with rituximab with standard treatment in lymphomas

Background

An international Phase III clinical trial in lymphoma was conducted to evaluate the efficacy and tolerability of a new rituximab-based therapeutic combination compared with the reference treatment in patients with lymphoma.

The primary objective was to measure the clinical benefit in a heavily pretreated population, while ensuring the quality and comparability of data across sites.

essai clinique international en maladie rare projet national de centralisation de données clinique en vie réelle, étude clinique de bioéquivalence, Étude clinique sur le diabète étude clinique sur la sécurité d'un agent de contraste

Pharmaspecific’s role

In this trial, Pharmaspecific’s involvement ensured a fast start-up and compliance with Good Clinical Practice (GCP). Its team also provided rigorous follow-up of data quality and harmonisation of imaging assessments across sites, contributing to the reliability of the study results.

étude observationnelle multicentrique en oncologie essai clinique de phase III en myélome multiple ; étude de syndromes coronaires aigus

Results

étude observationnelle multicentrique en oncologie essai clinique de phase II en oncologie thoracique étude clinique de sécurité post-autorisation essai clinique international de phase III en lymphome

High compliance with scheduled visits and follow-up windows

Successful standardisation of imaging and clinical response data

Strict adherence to protocol timelines and requirements

Key takeaways

This project highlights Pharmaspecific's ability to support an international Phase III clinical trial in lymphoma in a complex multicentre setting. Through its expertise in lymphoma clinical trials, its command of imaging data and patient follow-up, and its constant commitment to scientific and regulatory quality, Pharmaspecific contributes to the rigorous conduct of late-phase studies in haematology.
Medical Services

Explore our clinical case studies

  • Oncology
  • Haematology
  • Virology
  • Rare diseases
  • Cardiology
  • Medical devices

Securing the launch of a vaccine trial

Coordinated regulatory submissions in 6 countries simultaneously

Recherche clinique en virologie

Facilitating recruitment for an orphan disease

A patient concierge service to reduce the burden on a geographically dispersed population

Recherche clinique sur les maladies rares

Preparing for a regulatory inspection with confidence

An independent GCP audit to anticipate deviations before inspection

Recherche clinique en cardiologie